Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, reported financial results and provided business updates for the first quarter of 2023.
Moderna Reports First Quarter 2023 Financial Results and Provides Business Updates Read More »
Alvotech, a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced the initiation of Alvotech’s confirmatory patient study for AVT05, a biosimilar candidate to Simponi® and Simponi Aria®.
BioCardia®, Inc. announced it will report its financial results for the three months ended March 31, 2023 and provide a corporate update by conference call on Wednesday, May 10, 2023 at 4:30 PM ET.
Addex Therapeutics, a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced that it will issue its Q1 2023 financial results on Thursday, May 11, 2023.
XNK Therapeutics AB announced that the company’s autologous natural killer cell therapy candidate XNK04 will be evaluated in combination with an ADCC competent PD-L1 inhibitor in liver cancer under a research agreement with a global pharma company.
XNK Therapeutics Enters into Research Agreement with Global Pharma Company Read More »
AlzeCure Pharma AB announced that its interim report for the period January – March 2023 is now available on the company’s website.
AlzeCure Publishes its Interim Report for January – March 2023 Read More »
Hasten Biopharmaceutic Co., Ltd announced that it has acquired the commercial rights in China for Rocephin®, a long-acting, broad spectrum cephalosporin antibiotic, from Swiss multinational healthcare company, Roche.
Hasten Biopharma Acquires Commercial Rights in China for Roche’s Antibiotic Rocephin® Read More »
PureTech Health plc, a clinical-stage biotherapeutics company noted that its Founded Entity, Akili, Inc., a leading digital medicine company, announced topline results of the STARS-ADHD-Adult clinical trial evaluating the efficacy and safety of EndeavorRxⓇ in adults with attention-deficit/hyperactivity disorder.
Mekonos, Inc. has announced a new research collaboration with bit.bio, a synthetic biology company providing human cells for research, drug discovery and cell therapy.
Mekonos Announces Research Collaboration With bit.bio to Advance Cell Engineering Read More »
Reneo Pharmaceuticals, Inc. announced the pricing of its previously announced underwritten public offering of 6,875,000 shares of its common stock at a public offering price of $8.00 per share for aggregate gross proceeds of approximately $55.0 million, before deducting underwriting discounts and commissions and offering expenses.
Reneo Announces Pricing of Public Offering of Common Stock – May 04, 2023 Read More »
